Bayer Aktie News

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, pl...

Bayer Aktiengesellschaft / DE000BAY0017

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic reso...

Bayer DE000BAY0017 bleiben nach dem zweistelligen Kurssprung vom Vortag am Mittwoch im Fokus.

Shares of pharmaceutical conglomerate Bayer (BAYRY) are surging 12% on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review prior rulings on whether Roundup weed killer, produced by Bayer-owned Monsanto, needs a cancer risk warning label.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalan...

CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverGol Rise brings enhanced disease control to tough pathogens, like ascochyta, while also keeping the user ease of use top of mind. “EverGol Rise will be transformational for Canadian farmers,” says As...

Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company's bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.